Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tadaaki Yamada

Showing results (21-30 of 228) with videos related to

Pageof 23
Sort By:
Medicine|June 8, 2018
Treatment rationale and design of the RAMNITA study: A phase II study of the efficacy of docetaxel + ramucirumab for non-small cell lung cancer with brain metastasisKeiko Tanimura, Junji Uchino, Nobuyo Tamiya, et al.
Translational Lung Cancer Research|February 4, 2020
The role of the gut microbiome on the efficacy of immune checkpoint inhibitors in Japanese responder patients with advanced non-small cell lung cancerYuki Katayama, Tadaaki Yamada, Takayuki Shimamoto, et al.
Cancer Treatment Reviews|October 10, 2020
Association of immune checkpoint inhibitors with respiratory infections: A reviewRyosuke Hamashima, Junji Uchino, Yoshie Morimoto, et al.
Translational Lung Cancer Research|February 4, 2020
Rationale and design of a phase II trial of osimertinib as first-line treatment for elderly patients with epidermal growth factor receptor mutation-positive advanced non-small cell lung cancer (SPIRAL-0 study)Yusuke Chihara, Tadaaki Yamada, Junji Uchino, et al.
Medicine|June 8, 2018
Treatment rationale and design of the SPIRAL study: A phase II trial of osimertinib in elderly epidermal growth factor receptor T790M-positive nonsmall-cell lung cancer patients who progressed during prior EGFR-TKI treatmentJunji Uchino, Akira Nakao, Nobuyo Tamiya, et al.
Clinical Lung Cancer|March 26, 2019
Rationale and Design of a Phase II Trial of Osimertinib Combined With Bevacizumab in Patients With Untreated Epidermal Growth Factor Receptor-mutated Non-small-cell Lung Cancer and Malignant Pleural and/or Pericardial Effusion (SPIRAL II Study)Osamu Hiranuma, Junji Uchino, Tadaaki Yamada, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 17, 2009
Hepatocyte growth factor reduces susceptibility to an irreversible epidermal growth factor receptor inhibitor in EGFR-T790M mutant lung cancerTadaaki Yamada, Kunio Matsumoto, Wei Wang, et al.
British Journal of Cancer|May 31, 2024
Epithelial-mesenchymal transition status is a remarkable biomarker for the combination treatment with avutometinib and defactinib in KRAS-mutated non-small cell lung cancerAkihiro Yoshimura, Mano Horinaka, Takeshi Yaoi, et al.
Cancers|March 27, 2019
Safety and Usefulness of Cryobiopsy and Stamp Cytology for the Diagnosis of Peripheral Pulmonary LesionsTatsuya Imabayashi, Junji Uchino, Akihiro Yoshimura, et al.
Cancer Research|November 9, 2016
A Transcriptional Signature Identifies LKB1 Functional Status as a Novel Determinant of MEK Sensitivity in Lung AdenocarcinomaJacob M Kaufman, Tadaaki Yamada, Kyungho Park, et al.
Pageof 23

Showing results (21-30 of 228) with videos related to

Sort By:
Pageof 23
Medicine|June 8, 2018
Treatment rationale and design of the RAMNITA study: A phase II study of the efficacy of docetaxel + ramucirumab for non-small cell lung cancer with brain metastasisKeiko Tanimura, Junji Uchino, Nobuyo Tamiya, et al.
Translational Lung Cancer Research|February 4, 2020
The role of the gut microbiome on the efficacy of immune checkpoint inhibitors in Japanese responder patients with advanced non-small cell lung cancerYuki Katayama, Tadaaki Yamada, Takayuki Shimamoto, et al.
Cancer Treatment Reviews|October 10, 2020
Association of immune checkpoint inhibitors with respiratory infections: A reviewRyosuke Hamashima, Junji Uchino, Yoshie Morimoto, et al.
Translational Lung Cancer Research|February 4, 2020
Rationale and design of a phase II trial of osimertinib as first-line treatment for elderly patients with epidermal growth factor receptor mutation-positive advanced non-small cell lung cancer (SPIRAL-0 study)Yusuke Chihara, Tadaaki Yamada, Junji Uchino, et al.
Medicine|June 8, 2018
Treatment rationale and design of the SPIRAL study: A phase II trial of osimertinib in elderly epidermal growth factor receptor T790M-positive nonsmall-cell lung cancer patients who progressed during prior EGFR-TKI treatmentJunji Uchino, Akira Nakao, Nobuyo Tamiya, et al.
Clinical Lung Cancer|March 26, 2019
Rationale and Design of a Phase II Trial of Osimertinib Combined With Bevacizumab in Patients With Untreated Epidermal Growth Factor Receptor-mutated Non-small-cell Lung Cancer and Malignant Pleural and/or Pericardial Effusion (SPIRAL II Study)Osamu Hiranuma, Junji Uchino, Tadaaki Yamada, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 17, 2009
Hepatocyte growth factor reduces susceptibility to an irreversible epidermal growth factor receptor inhibitor in EGFR-T790M mutant lung cancerTadaaki Yamada, Kunio Matsumoto, Wei Wang, et al.
British Journal of Cancer|May 31, 2024
Epithelial-mesenchymal transition status is a remarkable biomarker for the combination treatment with avutometinib and defactinib in KRAS-mutated non-small cell lung cancerAkihiro Yoshimura, Mano Horinaka, Takeshi Yaoi, et al.
Cancers|March 27, 2019
Safety and Usefulness of Cryobiopsy and Stamp Cytology for the Diagnosis of Peripheral Pulmonary LesionsTatsuya Imabayashi, Junji Uchino, Akihiro Yoshimura, et al.
Cancer Research|November 9, 2016
A Transcriptional Signature Identifies LKB1 Functional Status as a Novel Determinant of MEK Sensitivity in Lung AdenocarcinomaJacob M Kaufman, Tadaaki Yamada, Kyungho Park, et al.
Pageof 23